A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Participants With Relapsed/Refractory Multiple Myeloma

  • STATUS
    Recruiting
  • End date
    May 1, 2027
  • participants needed
    121
  • sponsor
    Ichnos Sciences SA
Updated on 28 October 2022

Summary

This study is a first-in-human, Phase 1/2, open label study that will evaluate safety and efficacy of ISB 1442 in relapsed/refractory multiple myeloma (R/R MM).

Description

The study will be conducted in two phases:

  • Phase 1: Dose escalation in R/R MM
  • Phase 2: Dose expansions in select R/R MM
  • Cohort A: R/R MM
  • Cohort B: R/R MM Post-T-Cell Directed Therapy Participants will be treated at escalating dose levels in Phase 1 (dose-escalation phase) of the study. Once the safety of ISB 1442 is confirmed and a Recommended Phase 2 Dose (RP2D) is established in Phase 1 for a given indication, Phase 2 will be initiated for that indication.

Participants will receive ISB 1442, until disease progression, unacceptable toxicity, or any criterion for stopping the study drug or withdrawal from the trial occurs.

Details
Condition Relapsed/Refractory Multiple Myeloma
Treatment ISB 1442 SC injection escalating doses, ISB 1442 SC injection at RP2D
Clinical Study IdentifierNCT05427812
SponsorIchnos Sciences SA
Last Modified on28 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Male or female patients aged 18 years or older
Be willing and able to provide written informed consent and any locally required authorization (eg, Health Insurance Portability and Accountability Act of 1996 [HIPAA]) prior to any protocol related procedures, including screening evaluations
Phase 1: Patients with pathologically confirmed multiple myeloma (MM) who have progressed on or after standard therapy (relapsed/refractory [R/R] patients)
Must have received at least 3 prior lines of therapy, including PIs, IMiDs, and anti CD38 therapies either in combination or as a single agent; and must not be candidates for regimens known to provide clinical benefit. (Note: Patients in Australia may have received any of the therapies including PIs, IMiDs, and anti CD38 therapies either in combination or as a single agent; and must not be candidates for regimens known to provide clinical benefit )
Must have measurable M-protein (serum and/or 24-hr urine, or serum free light chains)
Phase 2: Patients with pathologically confirmed MM who have progressed on or after
standard therapy (R/R patients)
Cohort A: R/R MM
Must have received at least 3 prior lines of therapy, including PIs, IMiDs, and anti CD38 therapies either in combination or as a single agent
Must have measurable disease defined by at least 1 of the following abnormalities (as per IMWG criteria)
Serum M-protein ≥ 0.5 g/L (IgA ≥ 0.5 g/L), or
Urine light-chain (M-protein) of ≥ 200 mg/24 hours, or
Serum free light chain (sFLC) assay: involved free light chain (FLC) level ≥ 10 mg/dL provided sFLC ratio is abnormal
Cohort B: R/R MM Post-T-Cell Directed Therapy
Must have received at least 3 prior lines of therapy, including PIs, IMiDs and anti-CD38 therapies either in combination or as a single agent; and have relapsed and/or be refractory to a T-cell directed therapy including cellular therapies or T cell engagers
Must have measurable disease defined by at least 1 of the following abnormalities (as per IMWG criteria)
Serum M-protein ≥ 0.5 g/L (IgA ≥ 0.5 g/L), or
Urine light-chain (M-protein) of ≥ 200 mg/24 hours, or
sFLC assay: involved FLC level ≥ 10 mg/dL provided sFLC ratio is abnormal 5. Have a body weight ≥ 40.0 kg at screening. 6. Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or
less
\. Have life expectancy of at least 3 months (from date of informed consent
signing). 8. Have adequate organ function, including
Aspartate aminotransferase (AST, GOT) and alanine aminotransferase (ALT, GPT)
≤3.0 × ULN; bilirubin ≤1.5 × ULN. Patients with Gilbert's syndrome may have a
bilirubin level >1.5 × ULN, per discussion between the Investigator and
medical monitor
Estimated creatinine clearance ≥45 mL/min as calculated using the Cockcroft-Gault formula or 24-hour urine collection
Left ventricular ejection fraction (LVEF) ≥45% as assessed by echocardiogram (ECHO) or
multiple gated acquisition (MUGA) scan

Exclusion Criteria

Participants with relapsed disease where relapse is characterized only by minimal residual disease parameters (i.e., minimal residual disease positive)
Participants with MM with disease where the only measurable parameter is plasmacytoma
Received treatment with anti-CD38 antibodies or CD47 targeted therapies within 1 month of C1D1; systemic anticancer treatments within 14 days before the first dose of study drug (C1D1) or any investigational products within 5 half-lives of C1D1, whichever is appropriate to last therapy received. (eg, non-IMP IMiD, proteasome inhibitor could be considered to be eligible if there is at least 14 days after last dose before C1D1. Note: Treatment with a single course of glucocorticoids is allowed (maximum dose of corticosteroids should not exceed the equivalent of 160 mg [for example, 40 mg/d for 4 days] of dexamethasone). Hormonal therapy for prostate cancer or breast cancer (as adjuvant treatment), and treatment with bisphosphonates and receptor activator of nuclear factor kappa-Β ligand inhibitors are allowed
Received autologous stem cell transplantation within 12 weeks of C1D1
Current participation in another interventional study, including other clinical trials with investigational agents (including investigational vaccines or investigational medical device for disease under study) within 4 weeks of C1D1 and throughout the duration of this trial
Prior radiation therapy within 14 days of C1D1; or prior irradiation to > 25% of the bone marrow. Note: Prophylactic localized ("spot") radiation for areas of pain is allowed
Active malignant central nervous system involvement
Known to be refractory to platelet or RBC transfusions
Known severe allergic or anaphylactic reactions to human recombinant proteins or excipients used in the ISB 1442 formulation
QTc interval > 480 msec at screening using Fredericia's QT correction formula
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note